ELTP Stock: Elite Pharmaceuticals, Inc. Stock Price, Analysis & Insights
Get live eltp stock price $0.70, comprehensive Elite Pharmaceuticals, Inc. stock analysis, charts, news, and expert forecast. Real-time eltp stock data and investment insights.
Company Overview
Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development and manufacture of oral, controlled-release products and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Products and New Drug Applications for Branded Products. It owns, licenses, and contract manufactures various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Oxycodone HCl immediate release 5mg, 10mg, 15mg, 20mg, and 30mg tablets for pains under Roxycodone brand; Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets for central nervous system diseases under the Adderall brand, as well as Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the brand Loxapine; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, and infection. Further, the company is developing a range of abuse deterrent opioid products. The company was incorporated in 1997 and is headquartered in Northvale, New Jersey.
Company Information
- CEO
- Nasrat Hakim
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Employees
- 64
Contact Information
- Website
- https://www.elitepharma.com
- Address
- 165 Ludlow Avenue
- Country
- US
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 749.67M market capitalization
- Trading Volume: 648.32K shares traded today
- Price Range: 52-week range of $0.27 - $0.82
- Exchange: Listed on Other OTC
Financial Metrics
Market Analysis for Elite Pharmaceuticals, Inc.
Elite Pharmaceuticals, Inc. (ELTP) operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. With a current market capitalization of 749.67M, the company represents a significant player in its market. The stock is currently trading at $0.70 with a negativedaily change of 1.39%.
The company's 64 employee base and presence on the Other OTCexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -70.00, beta of 0.24, and 52-week price range from $0.27 to $0.82when evaluating investment opportunities.
Why Invest in Elite Pharmaceuticals, Inc.?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (Other OTC)
- • Experienced leadership under Nasrat Hakim
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.